Six new drug indications pharmacists and physicians should know about

Cabometyxcabozantinib tablets, Ipsen Biopharmaceuticals.REVISED INDICATION Now indicated for the treatment of advanced renal cell carcinoma in treatment-naïve adults with intermediate or poor risk, and in adults who have received prior therapy. (Formerly indicated for adults who had received prior vascular endothelial growth factor [VEGF]-targeted therapy. Also indicated for use in the treatment of hepatocellular carcinoma and differentiated thyroid carcinoma.)DOSAGE Consult product monograph for details.Constellalinaclotide capsules, AbbVie.NEW INDICATION Treatment of functional constipation in children six to 17 years of age. Contraindicated in children under six years of age because it may cause severe dehydration. (Also approved earlier for use in the treatment of irritable bowel syndrome with constipation [IBS-C] in adults and chronic idiopathic constipation in adults.)DOSAGE Functional constipation in children 6–17 years of age: 72 µg once daily on an empty stomach, at least 30 minutes before a meal. For children who are unable to swallow the capsules whole, the capsules can be opened and administered orally in applesauce or with water, or administered with water via a nasogastric or gastric tube; see detailed instructions in the product monograph.Dupixentdupilumab solution for subcutaneous injection, Sanofi-aventis.EXPANDED INDICATION Now indicated for the treatment of eosinophilic esophagitis in patients one year of age or older and weighing at least 15 kg. (Formerly indicated for this use in patients ≥ 12 years of age and weighing ≥ 40 kg. Also indicated for use in the treatment of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and prurigo nodularis.)DOSAGE Eosinophilic esophagitis: Dosage is based on body weight: 15 kg to < 30 kg—200 mg SC every other week; 30 kg to < 40 kg—300 mg SC every other week; ≥ 40 kg—300 mg SC every week.Imfinzidurvalumab concentrate for solution for IV infusion, AstraZeneca.NEW INDICATION First-line treatment of unresectable hepatocellular carcinoma, in combination with tremelimumab, in adults who require systemic therapy. (Also approved earlier for use as monotherapy for the first-line treatment of adults with unresectable hepatocellular carcinoma who require systemic therapy, as well as for use in the treatment of urothelial carcinoma, nonsmall cell lung cancer, small cell lung cancer and biliary tract cancer.)DOSAGE Unresectable hepatocellular carcinoma, in combination with tremelimumab: tremelimumab 300 mg as a single dose by IV infusion, followed by durvalumab 1500 mg by IV infusion on Day 1 of Cycle 1. Continue durvalumab 1500 mg IV as a single agent every four weeks, until disease progression or unacceptable toxicity occurs. Patients with a body weight of ≤ 30 kg must receive weight-based dosing; see product monograph for details.Keytrudapembrolizumab solution for IV infusion, Merck.NEW INDICATION Treatment of unresectable locally advanced or metastatic urothelial cancer (mUC), in combination with enfortumab vedotin, in adults with no prior systemic therapy for mUC. (Also approved for treatment of numerous other cancers; consult product monograph for details.)DOSAGE Unresectable locally advanced or metastatic urothelial cancer, in combination with enfortumab vedotin: pembrolizumab 200 mg every three weeks or 400 mg every six weeks administered as an IV infusion over 30 minutes. Use in combination with enfortumab vedotin 1.25 mg/kg by IV infusion over 30 minutes on Days 1 and 8 of each 21-day cycle.Reblozylluspatercept lyophilized powder for solution for SC injection, Bristol-Myers Squibb.NEW INDICATION Treatment of adults with transfusion-dependent anemia due to very low- to intermediate-risk myelodysplastic syndromes (MDS) who have not been previously treated with an erythropoiesis stimulating agent (ESA-naïve). (Also approved earlier for the treatment of adults with transfusion-dependent anemia resulting from very low- to intermediate-risk MDS who have failed or are unsuitable for erythropoietin-based therapy, and for treatment of adults with red blood cell transfusion-dependent anemia associated with beta-thalassemia.)DOSAGE Recommended starting dose is 1 mg/kg every three weeks by SC injection. Consult product monograph for details on dosage adjustment.

Six new drug indications pharmacists and physicians should know about

Register for free access or login.

Related Topics